Weekly Digest - 03-09 Jun 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 03-09 Jun 2023
Jun 06, 2023: Trodelvy (sacituzumab govitecan-hziy) / HR+/HER2- Metastatic Breast Cancer / Gilead Sciences: Reported encouraging Overall Survival benefits
- Gilead Science announced longer-term overall survival data from the Phase 3 TROPiCS-02 study evaluating Trodelvy vs Treatment of Physicians choice (TPC) in patients with HR+/HER2 Breast Cancer
- PFS rates for Trodelvy vs TPC were consistently higher at landmark milestones of 6, 12, and 18 months (45.6% vs. 29.4%, 21.7% vs. 8.4%, and 14.4 vs. 4.7%, respectively)
- Similarly, OS rates for Trodelvy vs. TPC were consistently higher at landmark milestones of 12, 18, and 24 months (60.9% vs. 47.1%, 39.2% vs. 31.7%, and 25.7% vs. 21.1%, respectively)
- Median OS was 13.6 months vs. 10.8 months in HER2 IHC0 group and 15.4 vs. 11.5 months HER2-low groups
